Click here to get full coverage on Trading the Move, Not the Narrative: (KROS) Edition - Stock Traders Daily

Trading the Move, Not the Narrative: (KROS) Edition  Stock Traders Daily

Trading the Move, Not the Narrative: (KROS) Edition - Stock Traders Daily

Click here to get full coverage on Ex-Lyell CFO and healthcare banker Charles Newton joins Keros board - Stock Titan

Ex-Lyell CFO and healthcare banker Charles Newton joins Keros board  Stock Titan

Ex-Lyell CFO and healthcare banker Charles Newton joins Keros board - Stock Titan

Click here to get full coverage on Keros Therapeutics, Inc. $KROS is Western Standard LLC's Largest Position - MarketBeat

Keros Therapeutics, Inc. $KROS is Western Standard LLC's Largest Position  MarketBeat

Keros Therapeutics, Inc. $KROS is Western Standard LLC's Largest Position - MarketBeat

Click here to get full coverage on Ask the Pros: How Kros Strain Dialed in Its Flagship Hazy IPA, Fairy Nectar - Craft Beer & Brewing

Ask the Pros: How Kros Strain Dialed in Its Flagship Hazy IPA, Fairy Nectar  Craft Beer & Brewing

Ask the Pros: How Kros Strain Dialed in Its Flagship Hazy IPA, Fairy Nectar - Craft Beer & Brewing

Click here to get full coverage on KROS Technical Analysis & ETF Price Forecast - Intellectia AI

KROS Technical Analysis & ETF Price Forecast  Intellectia AI

KROS Technical Analysis & ETF Price Forecast - Intellectia AI

Click here to get full coverage on KROS: Rinvatercept and elritercept advance in key trials, with strong cash runway into 2028 - TradingView

KROS: Rinvatercept and elritercept advance in key trials, with strong cash runway into 2028  TradingView

KROS: Rinvatercept and elritercept advance in key trials, with strong cash runway into 2028 - TradingView

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) Investor Outlook: Exploring The 53% Potential Upside - DirectorsTalk Interviews

Keros Therapeutics, Inc. (KROS) Investor Outlook: Exploring The 53% Potential Upside  DirectorsTalk Interviews

Keros Therapeutics, Inc. (KROS) Investor Outlook: Exploring The 53% Potential Upside - DirectorsTalk Interviews

Click here to get full coverage on Jason Kros - Men's Tennis Coach - Ole Miss Athletics - Hotty Toddy - Ole Miss Athletics

Jason Kros - Men's Tennis Coach - Ole Miss Athletics - Hotty Toddy  Ole Miss Athletics

Jason Kros - Men's Tennis Coach - Ole Miss Athletics - Hotty Toddy - Ole Miss Athletics

Click here to get full coverage on What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now? - Yahoo Finance

What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?  Yahoo Finance

What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now? - Yahoo Finance

Click here to get full coverage on Gateway Events - Kros Strain Beer Week Trivia - unothegateway.com

Gateway Events - Kros Strain Beer Week Trivia  unothegateway.com

Gateway Events - Kros Strain Beer Week Trivia - unothegateway.com

Click here to get full coverage on Keros Therapeutics (KROS) awards Chief Legal Officer 80,000 options - Stock Titan

Keros Therapeutics (KROS) awards Chief Legal Officer 80,000 options  Stock Titan

Keros Therapeutics (KROS) awards Chief Legal Officer 80,000 options - Stock Titan

Click here to get full coverage on Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - TradingView

Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?  TradingView

Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - TradingView

Click here to get full coverage on ADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal - Intellectia AI

ADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal  Intellectia AI

ADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal - Intellectia AI

Click here to get full coverage on Keros Therapeutics (KROS) CEO awarded 317,000 stock options with vesting hurdles - Stock Titan

Keros Therapeutics (KROS) CEO awarded 317,000 stock options with vesting hurdles  Stock Titan

Keros Therapeutics (KROS) CEO awarded 317,000 stock options with vesting hurdles - Stock Titan

Click here to get full coverage on Keros CEO to speak at Oppenheimer, TD Cowen and Leerink events - Stock Titan

Keros CEO to speak at Oppenheimer, TD Cowen and Leerink events  Stock Titan

Keros CEO to speak at Oppenheimer, TD Cowen and Leerink events - Stock Titan

Click here to get full coverage on Keros Therapeutics (KROS) CEO auto-sells 7,015 shares for tax withholding - Stock Titan

Keros Therapeutics (KROS) CEO auto-sells 7,015 shares for tax withholding  Stock Titan

Keros Therapeutics (KROS) CEO auto-sells 7,015 shares for tax withholding - Stock Titan

Click here to get full coverage on Keros Therapeutics (NASDAQ: KROS) lines up CEO talks at key conferences - Stock Titan

Keros Therapeutics (NASDAQ: KROS) lines up CEO talks at key conferences  Stock Titan

Keros Therapeutics (NASDAQ: KROS) lines up CEO talks at key conferences - Stock Titan

Click here to get full coverage on D. E. Shaw group discloses 3.9% Keros Therapeutics (KROS) ownership in 13G/A - Stock Titan

D. E. Shaw group discloses 3.9% Keros Therapeutics (KROS) ownership in 13G/A  Stock Titan

D. E. Shaw group discloses 3.9% Keros Therapeutics (KROS) ownership in 13G/A - Stock Titan

Click here to get full coverage on ExodusPoint entities disclose 0.04% Keros Therapeutics (KROS) stake in 13G/A filing - Stock Titan

ExodusPoint entities disclose 0.04% Keros Therapeutics (KROS) stake in 13G/A filing  Stock Titan

ExodusPoint entities disclose 0.04% Keros Therapeutics (KROS) stake in 13G/A filing - Stock Titan

Click here to get full coverage on $194.4M Tender Offer — Keros Therapeutics to Repurchase at $17.75; Part of $375M Program. Expires Nov. 18, 2025 - Stock Titan

$194.4M Tender Offer — Keros Therapeutics to Repurchase at $17.75; Part of $375M Program. Expires Nov. 18, 2025  Stock Titan

$194.4M Tender Offer — Keros Therapeutics to Repurchase at $17.75; Part of $375M Program. Expires Nov. 18, 2025 - Stock Titan

Click here to get full coverage on Andrew Kros EA SPORTS™ College Football 26 Player Ratings - National Championship - Electronic Arts Home Page

Andrew Kros EA SPORTS™ College Football 26 Player Ratings - National Championship  Electronic Arts Home Page

Andrew Kros EA SPORTS™ College Football 26 Player Ratings - National Championship - Electronic Arts Home Page

Click here to get full coverage on Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Hold" by Analysts  MarketBeat

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat

Click here to get full coverage on Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - Yahoo Finance

Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High?  Yahoo Finance

Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - Yahoo Finance

Click here to get full coverage on KROS vs. ARGX: Which Stock Is the Better Value Option? - Nasdaq

KROS vs. ARGX: Which Stock Is the Better Value Option?  Nasdaq

KROS vs. ARGX: Which Stock Is the Better Value Option? - Nasdaq

Click here to get full coverage on Investors in Keros Therapeutics (NASDAQ:KROS) have unfortunately lost 72% over the last year - Yahoo Finance

Investors in Keros Therapeutics (NASDAQ:KROS) have unfortunately lost 72% over the last year  Yahoo Finance

Investors in Keros Therapeutics (NASDAQ:KROS) have unfortunately lost 72% over the last year - Yahoo Finance

Click here to get full coverage on $375M Capital Return: Keros Therapeutics repurchases $181M, plans $194M tender offer by Oct 2025 - Stock Titan

$375M Capital Return: Keros Therapeutics repurchases $181M, plans $194M tender offer by Oct 2025  Stock Titan

$375M Capital Return: Keros Therapeutics repurchases $181M, plans $194M tender offer by Oct 2025 - Stock Titan

Click here to get full coverage on KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Yahoo Finance

KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026?  Yahoo Finance

KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Yahoo Finance

Click here to get full coverage on Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? - Yahoo Finance

Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?  Yahoo Finance

Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? - Yahoo Finance

Click here to get full coverage on Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher - Yahoo Finance

Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher  Yahoo Finance

Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher - Yahoo Finance

Click here to get full coverage on Is KROS' KER-065 the Next Breakthrough in DMD Space? - Yahoo Finance

Is KROS' KER-065 the Next Breakthrough in DMD Space?  Yahoo Finance

Is KROS' KER-065 the Next Breakthrough in DMD Space? - Yahoo Finance

Click here to get full coverage on Insider Sale: 10% owner at $KROS Sells 4,391,237 Shares | KROS Stock News - Quiver Quantitative

Insider Sale: 10% owner at $KROS Sells 4,391,237 Shares | KROS Stock News  Quiver Quantitative

Insider Sale: 10% owner at $KROS Sells 4,391,237 Shares | KROS Stock News - Quiver Quantitative

Click here to get full coverage on How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - Yahoo Finance

How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%  Yahoo Finance

How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - Yahoo Finance

Click here to get full coverage on Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why - Yahoo Finance

Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why  Yahoo Finance

Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why - Yahoo Finance

Click here to get full coverage on Popular Templeton restaurant and historic building for sale - The Gardner News

Popular Templeton restaurant and historic building for sale  The Gardner News

Popular Templeton restaurant and historic building for sale - The Gardner News

Click here to get full coverage on Keros Therapeutics (Nasdaq: KROS) to Repurchase 10.95M Shares for $194.4M in Tender Offer - Stock Titan

Keros Therapeutics (Nasdaq: KROS) to Repurchase 10.95M Shares for $194.4M in Tender Offer  Stock Titan

Keros Therapeutics (Nasdaq: KROS) to Repurchase 10.95M Shares for $194.4M in Tender Offer - Stock Titan

Click here to get full coverage on Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%  simplywall.st

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st

Click here to get full coverage on Keros Therapeutics (Nasdaq: KROS) completes $194M tender offer, buying 35.9% of shares - Stock Titan

Keros Therapeutics (Nasdaq: KROS) completes $194M tender offer, buying 35.9% of shares  Stock Titan

Keros Therapeutics (Nasdaq: KROS) completes $194M tender offer, buying 35.9% of shares - Stock Titan

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) Investor Outlook: Analyzing a 38.97% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

Keros Therapeutics, Inc. (KROS) Investor Outlook: Analyzing a 38.97% Potential Upside in the Biotech Sector  DirectorsTalk Interviews

Keros Therapeutics, Inc. (KROS) Investor Outlook: Analyzing a 38.97% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

Click here to get full coverage on Veteran Sivley bringing experience, leadership to 2026 USM pitching staff - WDAM-TV

Veteran Sivley bringing experience, leadership to 2026 USM pitching staff  WDAM-TV

Veteran Sivley bringing experience, leadership to 2026 USM pitching staff - WDAM-TV

Click here to get full coverage on KROS vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance

KROS vs. ARGX: Which Stock Is the Better Value Option?  Yahoo Finance

KROS vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance

Click here to get full coverage on Price-Driven Insight from (KROS) for Rule-Based Strategy - Stock Traders Daily

Price-Driven Insight from (KROS) for Rule-Based Strategy  Stock Traders Daily

Price-Driven Insight from (KROS) for Rule-Based Strategy - Stock Traders Daily

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates  Yahoo Finance

Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on KROS's Gary Determan still has love for Radio in 50th Season - Clinton Herald

KROS's Gary Determan still has love for Radio in 50th Season  Clinton Herald

KROS's Gary Determan still has love for Radio in 50th Season - Clinton Herald

Click here to get full coverage on Keros Therapeutics CEO to Present at Multiple Conferences - The Globe and Mail

Keros Therapeutics CEO to Present at Multiple Conferences  The Globe and Mail

Keros Therapeutics CEO to Present at Multiple Conferences - The Globe and Mail

Click here to get full coverage on 'A beer for everybody': Beer brewed in La Vista named official craft beer of the Huskers - KETV

'A beer for everybody': Beer brewed in La Vista named official craft beer of the Huskers  KETV

'A beer for everybody': Beer brewed in La Vista named official craft beer of the Huskers - KETV

Click here to get full coverage on Postgame Pint: Ben Doody reviews Kros Strain's Somewhere in Middle America IPA after Nebraska's win - Omaha World-Herald

Postgame Pint: Ben Doody reviews Kros Strain's Somewhere in Middle America IPA after Nebraska's win  Omaha World-Herald

Postgame Pint: Ben Doody reviews Kros Strain's Somewhere in Middle America IPA after Nebraska's win - Omaha World-Herald

Click here to get full coverage on Earnings Update: Keros Therapeutics, Inc. (NASDAQ:KROS) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance

Earnings Update: Keros Therapeutics, Inc. (NASDAQ:KROS) Just Reported And Analysts Are Boosting Their Estimates  Yahoo Finance

Earnings Update: Keros Therapeutics, Inc. (NASDAQ:KROS) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance

Click here to get full coverage on Is Keros Therapeutics Stock Built to Withstand More Downside? - Trefis

Is Keros Therapeutics Stock Built to Withstand More Downside?  Trefis

Is Keros Therapeutics Stock Built to Withstand More Downside? - Trefis

Click here to get full coverage on Y Intercept Hong Kong Ltd Lowers Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat

Y Intercept Hong Kong Ltd Lowers Holdings in Keros Therapeutics, Inc. $KROS  MarketBeat

Y Intercept Hong Kong Ltd Lowers Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat

Click here to get full coverage on Kathleen Kros - Tribute Archive

Kathleen Kros - Tribute Archive

Click here to get full coverage on PHOTOS: KROS hosts 'Voice of the Hawkkeyes' Gary Dolphin - Clinton Herald

PHOTOS: KROS hosts 'Voice of the Hawkkeyes' Gary Dolphin  Clinton Herald

PHOTOS: KROS hosts 'Voice of the Hawkkeyes' Gary Dolphin - Clinton Herald

Click here to get full coverage on Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan

Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event  Stock Titan

Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan

Click here to get full coverage on Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m - Investing.com

Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m  Investing.com

Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m - Investing.com

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - Yahoo Finance

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial  Yahoo Finance

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - Yahoo Finance

Click here to get full coverage on Royce Sheibal Obituary - Papillion, NE - Dignity Memorial

Royce Sheibal Obituary - Papillion, NE  Dignity Memorial

Royce Sheibal Obituary - Papillion, NE - Dignity Memorial

Click here to get full coverage on KROS: Takeda deal drove $243.7M revenue and $110.5M net income; $375M capital return plan announced - TradingView

KROS: Takeda deal drove $243.7M revenue and $110.5M net income; $375M capital return plan announced  TradingView

KROS: Takeda deal drove $243.7M revenue and $110.5M net income; $375M capital return plan announced - TradingView

Click here to get full coverage on Keros Therapeutics (KROS) Announces Share Repurchase Agreements - GuruFocus

Keros Therapeutics (KROS) Announces Share Repurchase Agreements  GuruFocus

Keros Therapeutics (KROS) Announces Share Repurchase Agreements - GuruFocus

Click here to get full coverage on Husker fans can cheer with beer: ‘Cornhusker Crusher’ debuts alongside custom Bud Light can - KOLN | Nebraska Local News, Weather, Sports | Lincoln, NE

Husker fans can cheer with beer: ‘Cornhusker Crusher’ debuts alongside custom Bud Light can  KOLN | Nebraska Local News, Weather, Sports | Lincoln, NE

Husker fans can cheer with beer: ‘Cornhusker Crusher’ debuts alongside custom Bud Light can - KOLN | Nebraska Local News, Weather, Sports | Lincoln, NE

Click here to get full coverage on Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path (KROS) - Seeking Alpha

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path (KROS)  Seeking Alpha

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path (KROS) - Seeking Alpha

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) Investor Outlook: Unveiling a 38% Potential Upside in Biotech - DirectorsTalk Interviews

Keros Therapeutics, Inc. (KROS) Investor Outlook: Unveiling a 38% Potential Upside in Biotech  DirectorsTalk Interviews

Keros Therapeutics, Inc. (KROS) Investor Outlook: Unveiling a 38% Potential Upside in Biotech - DirectorsTalk Interviews

Click here to get full coverage on Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS) - Seeking Alpha

Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS)  Seeking Alpha

Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS) - Seeking Alpha

Click here to get full coverage on Keros Therapeutics (KROS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $KROS - MarketBeat

Keros Therapeutics (KROS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $KROS  MarketBeat

Keros Therapeutics (KROS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $KROS - MarketBeat

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) Stock Analysis: Unpacking A 42% Potential Upside - DirectorsTalk Interviews

Keros Therapeutics, Inc. (KROS) Stock Analysis: Unpacking A 42% Potential Upside  DirectorsTalk Interviews

Keros Therapeutics, Inc. (KROS) Stock Analysis: Unpacking A 42% Potential Upside - DirectorsTalk Interviews

Click here to get full coverage on Downgrade Watch: Is KROS a good ESG investment - 2025 Momentum Check & AI Powered Market Entry Ideas - baoquankhu1.vn

Downgrade Watch: Is KROS a good ESG investment - 2025 Momentum Check & AI Powered Market Entry Ideas  baoquankhu1.vn

Downgrade Watch: Is KROS a good ESG investment - 2025 Momentum Check & AI Powered Market Entry Ideas - baoquankhu1.vn

Click here to get full coverage on Recap Report: What is the target price for KROS stock - Market Growth Review & Reliable Price Breakout Signals - baoquankhu1.vn

Recap Report: What is the target price for KROS stock - Market Growth Review & Reliable Price Breakout Signals  baoquankhu1.vn

Recap Report: What is the target price for KROS stock - Market Growth Review & Reliable Price Breakout Signals - baoquankhu1.vn

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) Stock Analysis: Exploring a Strong Revenue Growth and Potential 47.63% Upside - DirectorsTalk Interviews

Keros Therapeutics, Inc. (KROS) Stock Analysis: Exploring a Strong Revenue Growth and Potential 47.63% Upside  DirectorsTalk Interviews

Keros Therapeutics, Inc. (KROS) Stock Analysis: Exploring a Strong Revenue Growth and Potential 47.63% Upside - DirectorsTalk Interviews

Click here to get full coverage on Nebraska lawmakers overwhelmingly pass bill that helps small breweries self-distribute products - WOWT

Nebraska lawmakers overwhelmingly pass bill that helps small breweries self-distribute products  WOWT

Nebraska lawmakers overwhelmingly pass bill that helps small breweries self-distribute products - WOWT

Click here to get full coverage on 'I spent Christmas at an Irish League game,' says Dutch groundhopper - BBC

'I spent Christmas at an Irish League game,' says Dutch groundhopper  BBC

KROS

Price Chart

Key Statistics

Technicals

About KROS

Latest News

Trading the Move, Not the Narrative: (KROS) Edition - Stock Traders Daily

Ex-Lyell CFO and healthcare banker Charles Newton joins Keros board - Stock Titan

Keros Therapeutics, Inc. $KROS is Western Standard LLC's Largest Position - MarketBeat

Advanced Charts

Top Gainers

Top Losers